Skip to content

The Actual News

Stay informed without the news wearing you out.

New Cancer Pill Given Standing Ovation at Oncology Conference

New Cancer Pill Given Standing Ovation at Oncology Conference

Summary

A new pill called daraxonrasib, designed to treat pancreatic cancer, showed promising results by nearly doubling patient survival in a major late-stage trial. Doctors at a large cancer conference gave the drug a standing ovation after hearing about its success in blocking a protein that helps cancer grow.

Key Facts

  • Daraxonrasib targets a mutated protein called KRAS, which causes tumor growth in over 90% of pancreatic cancer cases.
  • Pancreatic cancer kills about 50,000 Americans yearly and has a very low five-year survival rate for advanced cases (3%).
  • The treatment lowers the risk of death by 60% compared to standard chemotherapy.
  • In the trial, patients using daraxonrasib lived an average of 13.2 months versus 6.6 months with chemotherapy.
  • Side effects led to stopping treatment in only 1.2% of patients taking daraxonrasib, much fewer than with chemotherapy (11.2%).
  • The results were presented at the 2026 ASCO Annual Meeting in Chicago and published in a leading medical journal.
  • Daraxonrasib is the first drug to effectively inhibit the KRAS protein across multiple genetic variants.
  • The drug was developed by Revolution Medicines, which funded the clinical study.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.